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▒ EDITORIAL ▒
Journal of Pathology and Translational Medicine (JPTM) is 
pleased to announce a special issue devoted to the current prac-
tices of thyroid fine-needle aspiration (FNA) cytology in Asian 
countries as a joint effort of members of the Working Group of 
Asian Thyroid FNA Cytology. Currently, this growing network 
of Asian thyroid pathologists includes representatives from 
China, India, Japan, the Philippines, South Korea, Taiwan, 
Thailand, Turkey, and Vietnam.
Asia, as the largest and most populous continent, comprises 
several geographic regions with notable ethnic, cultural and reli-
gious diversity. The different levels and pace of economic growth 
within these regions determines the development of local health 
systems. Most Asian countries are well integrated into the modern 
international medical community. Contemporary practices in various 
fields of medicine were established under a strong Western 
influence. On the other hand, Asian philosophy, traditional Chinese 
medicine, Ayurveda, and other conventional medical practices 
with deep historical roots are often integrated into advanced medical 
approaches.1,2
Consistent with its huge population, the Asian continent is the 
largest contributor to the worldwide prevalence of thyroid cancer. 
According to the GLOBOCAN estimates, 48% of all new thyroid 
cancer cases are diagnosed in Asia.3 In addition, the absolute 
number of patients with thyroid cancer increases each year, and 
this growth has recently been labeled a thyroid cancer epidemic, 
due to unexpectedly high increases compared to estimates.4 South 
Korea is the best example of this thyroid cancer “epidemic,” which 
has been proven to be largely caused by opportunistic screening.5 
The same epidemic in many Western countries with a growing 
incidence of thyroid cancer was later attributed to opportunistic 
screening also.6 As a result of these epidemiological shifts, thyroid 
cancer and thyroid nodules have attracted considerable attention 
from the medical community worldwide.
Leading medical centers in well-developed Asian countries 
have promoted innovative approaches and disseminated high-
quality evidence, which has profoundly influenced international 
practice.7,8 Numerous publications from Japan and Korea have 
laid the ground for national guidelines on the management of 
thyroid cancer and thyroid nodules, which are finely tuned to the 
local settings.9,10 At the same time, guidelines from less advanced 
Asian countries largely rely on international recommendations 
partially adjusted to lower economic standards.11-13
Thyroid FNA is a mainstay of preoperative diagnosis of thyroid 
nodules, which drives further decision making.14 This simple 
procedure is available globally and has been accepted as the 
first-line intervention in the workup of thyroid nodules, which can 
significantly reduce unnecessary surgery. Unlike in gynecologic 
cytopathology, evaluation of thyroid FNA is usually performed 
by surgical pathologists who tended to apply their own classification 
schemes used in histopathologic diagnosis of thyroid nodules. As 
a result, cytologic diagnoses applied to thyroid FNAs were not 
uniform and clear, but rather variable and vague. Furthermore, a 
substantial number of samples are found to be uncertain, indeter-
minate, equivocal, or suspicious, which can create confusion for the 
clinicians with regard to treatment planning. 
In the effort to standardize thyroid cytologic terminology and 
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to improve communication between pathologists and clinicians, 
a new reporting system encompassing six diagnostic categories 
was proposed around 10 years ago.15 Since that time, the Bethesda 
System for Reporting Thyroid Cytopathology (TBSRTC) has 
received universal acclaim and has been endorsed by numerous 
national and international societies in the fields of endocrinology, 
thyroidology, and cytopathology.16 Beyond TBSRTC, several 
countries, including the UK, Italy, and Japan, have established 
their own systems for reporting thyroid cytopathology.17-19 Nev-
ertheless, the terminology used in non-Bethesda reporting systems 
is easily adjustable to Bethesda diagnostic categories, which is 
important for comparison.
Each of the modern systems for reporting thyroid cytopathol-
ogy provides important statistical outputs, which serve as the 
quality control criteria. These criteria include (1) distribution of 
thyroid FNA samples by diagnostic category; (2) resection rate 
(RR), measured as a ratio of surgically excised nodules to all 
sampled thyroid nodules within a certain category; and (3) risk 
of malignancy (ROM) or the percentage of malignant nodules 
among all FNAs. ROM is important because it indicates the 
necessity of surgical treatment. The original TBSRTC estimated 
ROM ranges for diagnostic categories based on preceding liter-
ature.15 These estimates were further modified in meta-analyses 
to provide the actual ROM, summarized from the numerous 
single- or multi-center studies.20-23 
Most meta-analyses on thyroid FNA and TBSRTC have not 
included Asian publications.20-22 Only one meta-analysis included 
a fair number of original studies from Turkey, Korea, and Arabic 
countries.23 In fact, experience with thyroid FNA in Asia has 
been extensively reported. Recently, the results of a nationwide 
study covering more than 42,000 FNAs were presented by the 
Korean Society of Endocrine Pathologists.24 Japanese institutions 
have also shared their experience with the Japanese system of 
reporting thyroid FNA.18 There is a growing number of publi-
cations from India and China. Reports on thyroid cytology from 
Southeast Asia are less abundant and often non-systematic. 
Notwithstanding, we should note that even low-resource countries, 
for example, Bangladesh and Nepal, have been able to publish 
their experience with thyroid FNA.25,26 Once again, despite the 
efforts of Asian cytopathologists to share their data with the inter-
national community, their voice has not been recognized. Hope-
fully, output data on the use of TBSRTC from major Asian 
countries summarized in this special issue will contribute to future 
meta-analyses of the Bethesda system.
An important lesson learned after comparison of Asian and 
Western series is that the Asian experience varies in several aspects. 
Thyroid FNA studies disclosed low RR and high ROM for inde-
terminate nodules in Asian practice.27 This could be explained by 
Fig. 1. Members of the Working Group of Asian Thyroid FNA Cytology and hosts during the inaugural meeting of the 12th Asia and Oceania 
Thyroid Association (AOTA) congress in Busan, Korea (March 16, 2017). FNA, fine-needle aspiration. Left-to-right: Z. Liu (China), K. Kakudo 
(Japan), C.R. Lai (Taiwan), S. Satoh (Japan), S. Keelawat (Thailand), S. Canberk (Turkey), A. Bychkov (Thailand), S.W. Hong (Korea), D.E. 
Song (Korea), C.K. Jung (Korea), H.J. Kwon (Korea), M. Hirokawa (Japan), H.K. Chang (Korea).
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the more conservative management approach for indolent thyroid 
tumors compared to Western practice.28 As a result, borderline 
thyroid tumors, such as noninvasive follicular thyroid neoplasm 
with papillary-like nuclear features (NIFTP) and well-differenti-
ated tumor of uncertain malignant potential, are histologically 
rare in Asian countries.29,30 These differences are not acknowl-
edged worldwide, which continues to create confusion among experts 
due to this lack of communication. It should be reiterated that 
the Asian continent is a major contributor to the global prevalence 
of thyroid cancer, and that local experience cannot be ignored.
International communication is a key factor in disseminating 
knowledge and staying up-to-date. There are several interna-
tional forums held annually for pathologists in Asia, but until 
recently there were no active well-established networks for those 
practicing within the thyroid niche. The Working Group of 
Asian Thyroid FNA Cytology was established recently to promote 
communication among Asian pathologists and cytopathologists, 
to share experience in Asian practice, and to conduct multi-insti-
tutional studies. An inaugural meeting took place at the 12th Asia 
and Oceania Thyroid Association (AOTA) Congress in Busan, 
Korea on March 16, 2017 (Fig. 1). Despite its recent formation, 
several achievements have resulted from this joint effort. Senior 
group members released a book Thyroid FNA Cytology: Differen-
tial Diagnoses and Pitfalls, which was published in 2016 as the 
first English language textbook on thyroid FNA cytology from 
Asia.31 Several authors contributed to a special NIFTP issue of 
the Journal of Basic and Clinical Medicine.32-35 More original studies 
and reviews have been published28,29,36 or are currently in process. 
Presented herein is a collection of articles on the current practices 
of thyroid FNA cytology in Asian countries that highlights im-
portant aspects of this diagnostic technique, including details 
on operators and readers, sampling and preparation, and reporting 
systems and audit programs. Also included are original data 
collected from the authors of previous publications and statistics 
from literature review. The authors wish to thank JPTM for 
hosting this special issue. We hope that our contemporary reviews 
will serve as a useful reference for a wide variety of specialists 
involved in the management of patients with thyroid nodules 
and thyroid cancer.
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